Want to see LBRX full AI Analyst Report?
LBRX Stock Chart & Stats
$30.52
--
Market closed
$30.52
--
Day’s Range― - ―
52-Week Range$13.36 - $35.35
Previous CloseN/A
VolumeN/A
Average Volume (3M)239.05K
Market Cap
$886.11M
Enterprise Value$544.53M
Total Cash (Recent Filing)$365.64M
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,676,653
10 Day Avg. Volume318,803
30 Day Avg. Volume239,047
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.64K
Enterprise Value/Ebitda-13.94
Forecast
1Y Price Target
$47.67Price Target Upside56.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stronger Balance SheetThe 2025 balance-sheet improvement—equity of roughly $301M with only about $3.6M of debt—materially reduces near-term solvency risk and increases financial flexibility. This durable capital base supports multi-year clinical programs and lessens immediate financing pressure while trials progress.
Accelerated Pivotal TimelineMoving the pivotal NOVA-2 readout earlier and scheduling a pre-NDA meeting compresses development timing and creates a clearer regulatory path. This structural acceleration reduces program uncertainty, increases visibility into approval potential, and can meaningfully de-risk the lead asset over 12–18 months.
Multi-year Runway And Focused PipelineProjected runway into Q2 2029 gives management time to execute multiple planned clinical readouts without immediate financing. Combined with a focused CNS pipeline, this durable funding visibility improves the odds of advancing lead programs to pivotal milestones and reduces near-term dilution risk.
Bears Say
No Commercial RevenueAs a clinical-stage biopharma, LB Pharmaceuticals has no commercial revenue and relies entirely on R&D progress and financing. This structural lack of top-line cash inflows means the business cannot self-fund operations until product approvals and commercialization occur, constraining long-term sustainability.
Persistent Cash BurnConsistent negative operating and free cash flow demonstrates ongoing cash burn to fund trials. This structural funding requirement implies continued dependency on external capital, which can dilute shareholders or impose financing constraints if market access tightens before commercial revenues emerge.
History Of Balance-sheet StressThe company’s history of negative equity signals past financing shortfalls and reliance on capital raises. Even with 2025 improvement, that track record implies execution and financing risk remain, increasing the likelihood of future dilutive financings or tougher funding terms under adverse conditions.
LB Pharmaceuticals, Inc. News
LBRX FAQ
What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?
LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $35.34 in the past 12 months.
What is LB Pharmaceuticals, Inc.’s market cap?
LB Pharmaceuticals, Inc.’s market cap is $886.11M.
When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LB Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is LB Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued.
Does LB Pharmaceuticals, Inc. pay dividends?
LB Pharmaceuticals, Inc. does not currently pay dividends.
What is LB Pharmaceuticals, Inc.’s EPS estimate?
LB Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LB Pharmaceuticals, Inc. have?
LB Pharmaceuticals, Inc. has 28,676,653 shares outstanding.
What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LB Pharmaceuticals, Inc. Stock Smart Score
Company Description
LB Pharmaceuticals, Inc.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LBRX Stock 12 Month Forecast
Average Price Target
$47.67
▲(56.18% Upside)
Technical Analysis
Ownership Overview
24.62% Insiders
13.02% Mutual Funds
9.05% Other Institutional Investors
45.97% Public Companies and
Individual Investors